Therapeutic Antibody Engineering Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry |
|
| Author:
| Strohl, William R.
Strohl, Lila M. |
| Series title: | Woodhead Publishing Series in Biomedicine Ser. |
| ISBN: | 978-1-907568-37-4 |
| Publication Date: | Oct 2012 |
| Publisher: | Elsevier Science & Technology
|
| Imprint: | Woodhead Publishing Limited |
| Book Format: | Hardback |
| List Price: | USD $305.00 |
Book Description:
|
The field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an...
More DescriptionThe field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in their production. Following chapters cover a number of specific issues relating to different aspects of antibody engineering, including variable chain engineering, targets and mechanisms of action, classes of antibody and the use of antibody fragments, among many other topics. The last part of the book examines development issues, the interaction of human IgGs with non-human systems, and cell line development, before a conclusion looking at future issues affecting the field of therapeutic antibody engineering.